Visual Snow Syndrome Emerges as a Brain Network Disorder, Review Finds

For most people, the visual world is a stable, continuous picture. For patients with visual snow syndrome, it is overlaid by a relentless field of tiny, dynamic, flickering dots that resembles the static of an untuned television set. The disturbance persists across the entire visual field, in darkness and in daylight, with eyes open or closed, and it never switches off. A comprehensive narrative review published in the Journal of Neurology argues that this perplexing condition should no longer be viewed as a purely visual anomaly, but as a multisystem neuropsychiatric network disorder in which abnormal brain connectivity, cortical hyperexcitability, and limbic dysfunction converge to produce both perceptual disturbances and a heavy psychiatric burden.

The review, led by Qing Huang and colleagues, synthesizes epidemiological data, neuroimaging findings, electrophysiological studies, and treatment reports to build an integrated framework for the syndrome. Its central claim is provocative: the anxiety, depression, depersonalization, fatigue, and sleep disturbances that so often accompany visual snow may not simply be psychological reactions to a chronic and distressing symptom. Instead, they may be intrinsic expressions of the same underlying neurobiology, reflecting dysfunction in the shared circuits that govern perception, emotion regulation, and salience attribution. This reframing has significant implications for how clinicians diagnose, investigate, and ultimately treat the disorder.

Epidemiologically, visual snow syndrome appears to be far from rare. Cross-sectional studies conducted in Italy, the United Kingdom, and Russia have estimated prevalence at between 0.7 and 4.4 percent, using symptom-based screening questionnaires followed by clinical validation. An online survey found that 41.9 percent of respondents had experienced visual snow phenomena at some point, yet only 4.49 percent met the full diagnostic criteria of the International Classification of Headache Disorders, third edition. Most affected individuals screened in prevalence studies had never received a formal diagnosis before enrollment, underscoring how frequently the condition escapes clinical recognition. Cohorts typically show a female predominance and a mean age of roughly 25 to 30 years, although one large study of more than 1,100 patients found no significant sex difference and a mean age of 29.

Onset patterns are strikingly variable. Reported proportions of childhood-onset cases, in which symptoms have been present for as long as the patient can remember, range from 17.2 percent in a hospital-based outpatient study to 89.6 percent in an online survey, with two large cohorts suggesting approximately 40 percent. The review cautions that this phrase should not be equated with a truly congenital condition, although the data raise the possibility of a genetically predisposed congenital subtype whose true prevalence remains unknown. In other patients, onset follows a precipitating event: 42.3 percent of patients in one study reported a triggering event or associated comorbidity. Migraine is the most common, affecting roughly 50 to 70 percent of patients, and the likelihood of developing the syndrome is significantly elevated among people with migraine. Case reports implicate occipital ischemic stroke, hallucinogen persisting perception disorder associated with substances such as LSD and delta-8-tetrahydrocannabinol, selective serotonin reuptake inhibitor exposure, mild traumatic brain injury, infection, idiopathic intracranial hypertension, and ocular abnormalities. The emerging picture is of a disorder triggered by multiple environmental or pathological factors in genetically susceptible individuals.

The mechanistic evidence reviewed by the authors is where the network concept gains its force. Ultra-high-field 7 Tesla structural MRI has revealed that, despite the absence of gross morphometric abnormalities, patients show reduced T1 values following a clear caudorostral gradient, most pronounced in the occipital cortex and diminishing toward parietal, temporal, and prefrontal regions. Significant T1 reductions across multiple thalamic nuclei suggest alterations in neuronal density, membrane integrity, or microstructural organization, while voxel-based morphometry has documented increased gray matter volume at the right lingual gyrus–fusiform gyrus junction and in temporal and limbic lobes, alongside reduced volume in the superior temporal gyrus. Together, these findings map a distributed visual–thalamic–limbic architecture rather than a single lesioned locus.

Functional studies reinforce this distributed view. Magnetoencephalography has demonstrated increased gamma-band power in the primary visual cortex, a signature of cortical hyperexcitability, together with reduced alpha-phase-to-gamma-amplitude coupling, indicating impaired top-down inhibitory modulation from higher-order visual areas. Resting-state EEG shows reduced alpha-band power spectral density in the parietotemporal region, corresponding to secondary visual cortex dysfunction, and abnormally enhanced activity-dependent neuroplasticity has also been reported. Positron emission tomography reveals hypermetabolism in the right extrastriate cortex accompanied by hypometabolism in temporoparietal regions involved in auditory processing and attentional control. Functional MRI demonstrates abnormal connectivity within the visual network and disrupted connections involving the thalamus, basal ganglia, default mode network, and salience-attention systems, both at rest and during stimulation. EEG microstate analyses add evidence of unstable large-scale network dynamics, with reduced microstate duration and amplitude and abnormal transitions among auditory–visual, visual, and salience-related states. In this model, patients cannot effectively suppress internally generated visual noise, allowing it to enter conscious awareness as continuous static.

Crucially, the same circuitry offers a bridge to the psychiatric dimension. Neuroimaging has identified increased gray matter volume in bilateral limbic structures, including the anterior cingulate cortex, insula, and prefrontal cortex, along with hypometabolism in the hippocampal–parahippocampal region. Reduced parahippocampal–occipital connectivity correlates significantly with subjective distress, suggesting disruption of a perception–emotion–inhibition loop. Receptor-enriched connectivity analyses point to abnormalities in glutamatergic and serotonergic pathways within the anterior cingulate, insula, orbitofrontal cortex, and visual association areas. Notably, psychiatric symptom severity does not differ between childhood-onset and later-onset patients, and longitudinal studies show that anxiety and depressive symptoms remain stable over time, patterns more consistent with shared neurobiology than with purely reactive distress. Familial aggregation adds a genetic dimension: 2.4 to 10 percent of first-degree relatives are affected, and migraine prevalence among relatives ranges from 9.4 to 56 percent, hinting at shared vulnerability, though no genome-wide association or linkage studies have yet been performed.

The clinical burden is substantial. Depressive symptoms affect between 14.1 and 53 percent of patients depending on the instrument and design, while anxiety symptoms range from 15.4 to 49 percent; longitudinal assessments found lifetime rates of 41.4 percent for depression and 44.8 percent for anxiety, and symptom severity correlates with visual symptom severity. Approximately 45 percent of patients experience depersonalization, with a quarter reaching clinical threshold. Sleep is frequently disrupted, with 44.8 percent reporting difficulty initiating sleep due to visual interference in darkness, and 49.6 percent meeting criteria for clinically significant fatigue. Quality of life is markedly impaired across mental health, social functioning, and role-emotional domains, and recent work shows that self-efficacy and quality of life sequentially mediate the relationship between symptom burden and adverse outcomes including depression and suicidal ideation, identifying psychosocial mechanisms as actionable intervention targets.

Treatment remains the weakest link. Pharmacological options are largely empirical and modestly effective: lamotrigine produced partial improvement in 19.2 percent of patients in one study with no complete remissions and adverse reactions in half of users, while topiramate response rates range from 15.4 to 28.5 percent. A survey of 400 patients found that antidepressants, antiepileptic drugs, antibiotics, and benzodiazepines were generally ineffective and often poorly tolerated. By contrast, non-pharmacological approaches show encouraging preliminary signals. Tinted lenses, particularly yellow and blue spectral filters, reduce the intensity, duration, and frequency of visual snow in 80 to 92 percent of individuals and improve palinopsia and photophobia by roughly 50 percent on average. Repetitive transcranial magnetic stimulation targeting the visual cortex or bilateral lingual gyri has shown favorable safety and preliminary efficacy, and prolonged exposure to high-contrast dynamic visual noise can reduce or temporarily eliminate symptoms. Mindfulness-based cognitive therapy has demonstrated dual benefits for visual symptoms and psychological distress, plausibly by modulating visual network connectivity through enhanced attentional flexibility and non-reactive awareness. Patients also report that darkness, bright light, stress, alcohol, sleep deprivation, and prolonged screen exposure worsen symptoms, while adequate sleep, stress reduction, meditation, and regular exercise help.

The review’s authors are careful to note that much of the current evidence derives from cross-sectional, retrospective, or uncontrolled studies, so causal relationships among visual symptoms, network dysfunction, and psychiatric manifestations must be interpreted cautiously. Yet the convergence of structural, functional, electrophysiological, and neurochemical findings on a single integrated model is difficult to ignore. They call for multidisciplinary research integrating neurology, psychiatry, neuroimaging, electrophysiology, and genetics, including Mendelian randomization, polygenic risk scoring, and multi-omics approaches, to identify biomarkers linking symptom dimensions to specific network and molecular alterations. For a condition that affects as many as one in twenty-five people by some estimates yet remains routinely missed, recognizing visual snow syndrome as a genuine neuropsychiatric network disorder may be the first step toward precision diagnosis and, eventually, effective therapy.

Subject of Research: Visual snow syndrome as a neuropsychiatric network disorder involving visual cortical hyperexcitability, thalamocortical dysrhythmia, and limbic dysfunction

Article Title: Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives

Article References: Huang, Q., Wang, J., Zhao, L., Yu, X., Wang, W., Wang, Z., & Liu, Y. (2026). Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives. Journal of Neurology, 273(10), Article 610. https://doi.org/10.1007/s00415-026-14137-w

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14137-w

Keywords: visual snow syndrome, neuropsychiatric disorders, thalamocortical dysrhythmia, functional connectivity, migraine, depersonalization, neuroimaging, transcranial magnetic stimulation, tinted lenses, mindfulness-based cognitive therapy, anxiety, depression